<< Back to companies search


Relitect are developing a novel technology for the detection of binding events, which can be used for the analysis of proteins, small molecules and nucleic acids.


The Relitect proprietary technology enables highly sensitive detection of biomarkers or other analytes in a label free multiplexed format, using small sample volumes.


Relitect’s approach has potential for utilisation across the clinical diagnostics and life sciences industries.




BioCity Glasgow


Company Type

Lab and office



Enabling technology